Interferon-α2b Treatment for COVID-19
The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adul...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01061/full |
id |
doaj-f6cacbbff71a4a98b10646f9338e247d |
---|---|
record_format |
Article |
spelling |
doaj-f6cacbbff71a4a98b10646f9338e247d2020-11-25T03:45:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-05-011110.3389/fimmu.2020.01061551312Interferon-α2b Treatment for COVID-19Qiong Zhou0Virginia Chen1Casey P. Shannon2Xiao-Shan Wei3Xuan Xiang4Xu Wang5Zi-Hao Wang6Scott J. Tebbutt7Scott J. Tebbutt8Tobias R. Kollmann9Eleanor N. Fish10Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaPrevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, CanadaPrevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, CanadaDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaPrevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, CanadaDivision of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, CanadaSystems Vaccinology, Center for Precision Health, Telethon Kids Institute, Nedlands, WA, AustraliaToronto General Hospital Research Institute, University Health Network and Department of Immunology, University of Toronto, Toronto, ON, CanadaThe global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases.https://www.frontiersin.org/article/10.3389/fimmu.2020.01061/fullinterferonCOVID-19viral sheddingIL-6inflammationARDS |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qiong Zhou Virginia Chen Casey P. Shannon Xiao-Shan Wei Xuan Xiang Xu Wang Zi-Hao Wang Scott J. Tebbutt Scott J. Tebbutt Tobias R. Kollmann Eleanor N. Fish |
spellingShingle |
Qiong Zhou Virginia Chen Casey P. Shannon Xiao-Shan Wei Xuan Xiang Xu Wang Zi-Hao Wang Scott J. Tebbutt Scott J. Tebbutt Tobias R. Kollmann Eleanor N. Fish Interferon-α2b Treatment for COVID-19 Frontiers in Immunology interferon COVID-19 viral shedding IL-6 inflammation ARDS |
author_facet |
Qiong Zhou Virginia Chen Casey P. Shannon Xiao-Shan Wei Xuan Xiang Xu Wang Zi-Hao Wang Scott J. Tebbutt Scott J. Tebbutt Tobias R. Kollmann Eleanor N. Fish |
author_sort |
Qiong Zhou |
title |
Interferon-α2b Treatment for COVID-19 |
title_short |
Interferon-α2b Treatment for COVID-19 |
title_full |
Interferon-α2b Treatment for COVID-19 |
title_fullStr |
Interferon-α2b Treatment for COVID-19 |
title_full_unstemmed |
Interferon-α2b Treatment for COVID-19 |
title_sort |
interferon-α2b treatment for covid-19 |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2020-05-01 |
description |
The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases. |
topic |
interferon COVID-19 viral shedding IL-6 inflammation ARDS |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2020.01061/full |
work_keys_str_mv |
AT qiongzhou interferona2btreatmentforcovid19 AT virginiachen interferona2btreatmentforcovid19 AT caseypshannon interferona2btreatmentforcovid19 AT xiaoshanwei interferona2btreatmentforcovid19 AT xuanxiang interferona2btreatmentforcovid19 AT xuwang interferona2btreatmentforcovid19 AT zihaowang interferona2btreatmentforcovid19 AT scottjtebbutt interferona2btreatmentforcovid19 AT scottjtebbutt interferona2btreatmentforcovid19 AT tobiasrkollmann interferona2btreatmentforcovid19 AT eleanornfish interferona2btreatmentforcovid19 |
_version_ |
1724508678437994496 |